This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Brief report: Secukinumab provides significant and...

Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis.

Read time: 1 mins
Published:1st Aug 2016
Author: van der Heijde D,Landew RB,Mease PJ,McInnes IB, Conaghan PG, Pricop L,et al.
Availability: Free full text
Ref.:Arthritis Rheumatol. 2016;68(8):1914-21
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest